Cheplapharm Drug Patent Portfolio

Cheplapharm owns 7 orange book drugs protected by 14 US patents with Zyprexa having the least patent protection, holding only 1 patent. And Valcyte with maximum patent protection, holding 4 patents. Given below is the list of Cheplapharm's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8889109 Pharmaceutical dosage forms comprising valganciclovir hydrochloride 11 Dec, 2027
Active
US9642911 Pharmaceutical dosage forms comprising valganciclovir hydrochloride 11 Dec, 2027
Active
US6169084 2-methyl-thieno-benzodiazepine formulation 30 Sep, 2018 Expired
US6004996 Tetrahydrolipstatin containing compositions 06 Jul, 2018 Expired
US6142145 Inhalation device 08 May, 2018 Expired
US7143764 Inhalation device 13 Mar, 2018 Expired
US6027714 Formulation for inhalation 09 Jan, 2018 Expired
US6287540 Formulation for inhalation 09 Jan, 2018 Expired
US6004996 Tetrahydrolipstatin containing compositions 06 Jan, 2018 Expired
US6960577 Combination therapy for treatment of refractory depression 01 Nov, 2017 Expired
US6083953 2- (2-amino-1,6-dihydro-6-oxo-purin-9-yl) methoxy-1,3- propanediol derivative 29 Sep, 2015 Expired
US6083953 2- (2-amino-1,6-dihydro-6-oxo-purin-9-yl) methoxy-1,3- propanediol derivative 29 Mar, 2015 Expired
US5472949 N4 -(substituted-oxycarbonyl)-5'-deoxy-5-fluorocytidine compounds, compositions and methods of using same 14 Jun, 2014 Expired
US5472949 N4 -(substituted-oxycarbonyl)-5'-deoxy-5-fluorocytidine compounds, compositions and methods of using same 14 Dec, 2013 Expired


Given below is the list of recent legal activities going on the following drug patents of Cheplapharm.

Activity Date Patent Number
Patent litigations
Email Notification 30 Aug, 2022 US9642911
Change in Power of Attorney (May Include Associate POA) 30 Aug, 2022 US9642911
Correspondence Address Change 26 Aug, 2022 US9642911
Change in Power of Attorney (May Include Associate POA) 25 Aug, 2022 US8889109
Correspondence Address Change 24 Aug, 2022 US8889109
Payment of Maintenance Fee, 8th Year, Large Entity 12 Apr, 2022 US8889109
Payment of Maintenance Fee, 4th Year, Large Entity 28 Sep, 2020 US9642911
Surcharge for Late Payment, Large Entity 21 Aug, 2018 US8889109
Payment of Maintenance Fee, 4th Year, Large Entity 21 Aug, 2018 US8889109
Maintenance Fee Reminder Mailed 02 Jul, 2018 US8889109
Recordation of Patent Grant Mailed 09 May, 2017 US9642911
Patent Issue Date Used in PTA Calculation 09 May, 2017 US9642911
Email Notification 21 Apr, 2017 US9642911
Issue Notification Mailed 19 Apr, 2017 US9642911
Dispatch to FDC 06 Apr, 2017 US9642911


Cheplapharm's Drug Patent Litigations

Cheplapharm's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on May 31, 2005, against patent number US7143764. The petitioner , challenged the validity of this patent, with ALLAN DAGSLAND et al as the respondent. Click below to track the latest information on how companies are challenging Cheplapharm's patents.

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US7143764 May, 2005 Decision
(31 Mar, 2006)
ALLAN DAGSLAND et al


Cheplapharm's Family Patents

Cheplapharm drugs have patent protection in a total of 31 countries. It's US patent count contributes only to 20.5% of its total global patent coverage. 5 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Family Patents



Cheplapharm Drug List

Given below is the complete list of Cheplapharm's drugs and the patents protecting them.


1. Pulmicort Flexhaler

Pulmicort Flexhaler is protected by 4 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US6142145 Inhalation device 08 May, 2018
(6 years ago)
Expired
US7143764 Inhalation device 13 Mar, 2018
(6 years ago)
Expired
US6027714 Formulation for inhalation 09 Jan, 2018
(6 years ago)
Expired
US6287540 Formulation for inhalation 09 Jan, 2018
(6 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Pulmicort Flexhaler's drug page


2. Valcyte

Valcyte is protected by 4 patents, out of which 2 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8889109 Pharmaceutical dosage forms comprising valganciclovir hydrochloride 11 Dec, 2027
(3 years from now)
Active
US9642911 Pharmaceutical dosage forms comprising valganciclovir hydrochloride 11 Dec, 2027
(3 years from now)
Active
US6083953
(Pediatric)
2- (2-amino-1,6-dihydro-6-oxo-purin-9-yl) methoxy-1,3- propanediol derivative 29 Sep, 2015
(9 years ago)
Expired
US6083953 2- (2-amino-1,6-dihydro-6-oxo-purin-9-yl) methoxy-1,3- propanediol derivative 29 Mar, 2015
(9 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Valcyte's drug page


3. Xeloda

Xeloda is protected by 2 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US5472949
(Pediatric)
N4 -(substituted-oxycarbonyl)-5'-deoxy-5-fluorocytidine compounds, compositions and methods of using same 14 Jun, 2014
(10 years ago)
Expired
US5472949 N4 -(substituted-oxycarbonyl)-5'-deoxy-5-fluorocytidine compounds, compositions and methods of using same 14 Dec, 2013
(10 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Xeloda's drug page


4. Xenical

Xenical is protected by 2 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US6004996
(Pediatric)
Tetrahydrolipstatin containing compositions 06 Jul, 2018
(6 years ago)
Expired
US6004996 Tetrahydrolipstatin containing compositions 06 Jan, 2018
(6 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Xenical's drug page


5. Zyprexa

Zyprexa is protected by 1 patent, which has expired already. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US6960577 Combination therapy for treatment of refractory depression 01 Nov, 2017
(6 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zyprexa's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

6. Zyprexa Relprevv

Zyprexa Relprevv is protected by 1 patent, which has expired already. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US6169084 2-methyl-thieno-benzodiazepine formulation 30 Sep, 2018
(6 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zyprexa Relprevv's drug page


7. Zyprexa Zydis

Zyprexa Zydis is protected by 1 patent, which has expired already. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US6960577 Combination therapy for treatment of refractory depression 01 Nov, 2017
(6 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zyprexa Zydis's drug page